Orion Oyj

ORNBV

FI0009014377

Pharmaceuticals

Market Closed - Nasdaq Helsinki Other stock markets 12:00:00 2025-07-07 EDT			After hours 15:24:03
63.40 ^EUR	+0.48%		63.25	-0.24%

06-20	Orion Corporation Recommends Third Indication for Darolutamide for Patients with Advanced Prostate Cancer	CI
06-20	Bayer, Orion's Prostate Cancer Treatment Recommended for EU Approval in Third Indication	MT

Orion, Shilpa Medicare Enter Commercial Deal for Albumin Product in Europe

Published on 2025-05-23 at 06:50

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Orion Oyj

Orion Corporation Recommends Third Indication for Darolutamide for Patients with Advanced Prostate Cancer	06-20	CI
Bayer, Orion's Prostate Cancer Treatment Recommended for EU Approval in Third Indication	06-20	MT
CHMP Recommends Third Indication For Darolutamide For Patients With Advanced Prostate Cancer	06-20	RE
Orion Extend Research, Licensing Deal for Antibody-drug Conjugates with Glykos Finland	06-17	MT
Orion, Glykos Announce Extension Of Research Collaboration, Licensing Agreement	06-17	RE
Orion and Glykos Announce the Extension of Their Research Collaboration and Licensing Agreement for the Development of Next-Generation ADCs	06-17	CI
US FDA Approves New Indication for Bayer, Orion's Prostate Cancer Treatment	06-03	MT
U.S. FDA Approves Third Indication of Darolutamide for Patients with Advanced Prostate Cancer	06-03	CI
Orion, Shilpa Medicare Enter Commercial Deal for Albumin Product in Europe	05-23	MT
Orion Signs Agreement With Shilpa Medicare	05-23	RE
Orion Corporation Announces Agreement with Shilpa Medicare for Recombinant Human Albumin for European Market	05-23	CI
Orion Oyj - Analyst/Investor Day	05-22
Aktiespararna is adding Orion and Storytel to its small-cap portfolio.	05-08	FW
Orion to License Criceto's Parkinson's Rescue Spray	04-25	MT
Orion And Criceto Announce License Agreement For Aporon	04-25	RE
Carnegie Group Upgrades Orion to Buy, Lifts PT	04-24	MT
OP Corporate Bank raises Orion to increase (decrease), target price 59 euros - BN	04-24	FW
Carnegie upgrades Orion to buy (hold), target price 57 euro (55) - BN	04-24	FW
SEB upgrades Orion to Buy (Hold), target price EUR 57 - BN	04-24	FW
Orion Oyj, Q1 2025 Earnings Call, Apr 23, 2025	04-23
Orion Affirms FY25 Net Sales, Operating Profit Outlook	04-23	MT
Orion Q1 Sales Up At EUR 354.6 Million	04-23	RE
Better than expected from Orion - reiterates forecast	04-23	FW
Orion Oyj Reports Earnings Results for the First Quarter Ended March 31, 2025	04-23	CI
Orion to Wind Down Finnish Unit	04-15	MT

Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - generic, OTC and biosimilar drugs (43.4%); - patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - animal health products (8.7%); - pharmaceutical ingredients and outsourcing services (6.2%). Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%). Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).

Employees

3,943

Sector

Pharmaceuticals

Calendar

07-18 - Q2 2025 Earnings Release

More about the company